Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$50.90 USD
+0.80 (1.60%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $50.83 -0.07 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
VKTX 50.90 +0.80(1.60%)
Will VKTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VKTX
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
Other News for VKTX
Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success
Commit To Buy Viking Therapeutics At $30, Earn 22.7% Using Options
3 Undervalued Biotech Stocks With Breakout Potential
Smart Money Is Betting Big In VKTX Options
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition